Separately, Zacks Investment Research cut OpGen from a buy rating to a hold rating in a research note on Wednesday, November 7th.
OPGN opened at $1.05 on Wednesday. The company has a quick ratio of 1.43, a current ratio of 1.56 and a debt-to-equity ratio of 0.28. OpGen has a 52 week low of $1.02 and a 52 week high of $7.60.
OpGen (NASDAQ:OPGN) last released its earnings results on Tuesday, November 13th. The medical research company reported ($0.53) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.02. The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.56 million. OpGen had a negative return on equity of 238.35% and a negative net margin of 395.63%. As a group, sell-side analysts anticipate that OpGen will post -2.19 EPS for the current year.
A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC acquired a new stake in shares of OpGen Inc (NASDAQ:OPGN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned about 0.99% of OpGen at the end of the most recent quarter. 4.08% of the stock is currently owned by institutional investors and hedge funds.
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Read More: What is the S&P 500 Index?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.